Duke-NUS celebrates 20 years of medical innovation with largest ever graduating class
Duke-NUS Medical School's Class of 2025 graduates 121 medical and doctoral students, including MDs, MD-PhDs, PhDs, and masters' degrees
Landmark first batch of Masters in Patient Safety and Healthcare Quality graduates, unique to Southeast Asia
Inaugural graduates from conditional admissions pathways with NUS and SUTD
41% of MD and MD-PhD graduates made bold mid-career shifts from fields such as law, PR, accounting and mental health support
SINGAPORE, May 31, 2025 /PRNewswire/ — Celebrating 20 years of transformative medical education, Duke-NUS Medical School graduated its largest cohort yet today, the Class of 2025, in a vibrant ceremony at the Ngee Ann Kongsi Auditorium in Academia attended by guest-of-honour Mr Ong Ye Kung, Minister for Health.
Marking a strategic milestone for Duke-NUS, the graduating class included 72 Doctor of Medicine (MD) graduates—five of whom are also earning PhDs—and 27 PhD candidates from the Integrated Biology and Medicine, Quantitative Biology and Medicine and Clinical and Translational Sciences programmes.
Among the MD graduates was the first group of individuals emerging from the Duke-NUS conditional admissions pathways with the National University of Singapore (NUS) and the Singapore University of Technology and Design (SUTD). These pathways are designed to attract talent from engineering, information technology and other undergraduate programmes.
Dean Professor Thomas Coffman said: 'Collaborating with seven partner universities, including Duke University and NUS, these pathways are designed to allow students to earn a first degree in diverse academic majors while providing an opportunity to seamlessly transition into medicine. It's a powerful model for developing doctors who are outstanding clinicians but also bring valuable multi-disciplinary skills into our healthcare system.'
This cohort also includes the inaugural batch of graduates of the Master's in Patient Safety and Healthcare Quality (MPSHQ) programme, the first of its kind in Southeast Asia. The MPSHQ is focused on building highly reliable healthcare systems that are of consistent quality and safety.
The Class of 2025 represents Duke-NUS' commitment to broadening the skillset and experience of our students, with 41 per cent of MD and MD-PhD graduates having transitioned mid-career from professions that include law, public relations, accounting and mental health peer support. Additionally, 58 per cent of the Class of 2025's graduates are women, underscoring the School's dedication to fostering diversity in the learning environment.
Said Dr Faith Wong Pih Yng, previously a modelmaking student and senior peer support specialist at Singapore's Institute of Mental Health, now MD graduate, 'Among the many hospital postings, what stood out most vividly was assisting in and witnessing childbirth—the intense anticipation and joy of welcoming a new life into the world was simply unmatched. Ultimately, however, the memories I cherish most are the countless hours spent with my classmates, supporting one another and peer-teaching.'
Duke-NUS MD graduates received their degrees, awarded jointly by Duke University and the National University of Singapore, in front of friends and family, as well as notable guests, including Duke University School of Medicine Dean Professor Mary Klotman, SingHealth Group CEO Professor Ng Wai Hoe, and keynote speaker, Dr Amy Abernethy, member of Duke University's board of trustees and co-founder of Highlander Health.
Caring and compassion underlines the Class of 2025's accomplishments, especially beyond academia. Partaking in a wealth of community service projects, some of their cohort, such as Dr Dana Chow Wai Shin, MD, started the Healthy to Thrive initiative, the first Duke-NUS-led public health screening event dedicated to migrant workers.
The cohort was also recognised for their outstanding achievements, which were given out the night before. Awards such as the Singapore Medical Association-Lee Foundation Prizes and Teamsmanship Awards presented to graduates who demonstrated excellence in academics, community service, and leadership.
In the aspect of research and scholarship, the Class of 2025 did not flag, publishing an exceptional 253 papers and publications in their time at Duke-NUS, several as first authors in prominent journals such as Nature Medicine, Immunity and EMBO Molecular Medicine. MD-PhD graduate Dr Katherine Nay Yaung, first author on a paper published in Lancet Rheumatology, wrote about artificial intelligence and high-dimensional technologies to diagnose and treat autoimmune diseases, and PhD graduate Dr Aishwarya Prakash, named first author and published in American Heart Association Journal, who found a type of peptide to have protective qualities for the heart after sustaining damage.
'The conversations I've had with patients emphasise a shift towards continuity of care and empowering individuals to make their own health choices. In moments where I feel overwhelmed, I remind myself that being a small part of each patient's journey has been a privilege,' said Dr Pang Wui Ming Jeremy, recipient of the SingHealth Prize in Family Medicine, Singapore Medical Association-Lee Foundation Teamsmanship Award for exemplary team values in medicine and Duke-NUS Achievement Prize.
As Duke-NUS enters its third decade, the School continues to redefine medical education and research, nurturing the next generation of healthcare leaders who are not just exceptional doctors but visionary innovators ready to make an impact in Singapore and beyond.
About Duke-NUS Medical School
Duke-NUS is Singapore's flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
For more information, please visit www.duke-nus.edu.sg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 days ago
- The Star
S'poreans can test for genetic condition causing high cholesterol levels under new programme
The new genetic testing programme for familial hypercholesterolaemia comes amid broader efforts to enhance preventive care in Singapore. - AFP SINGAPORE: Eligible Singapore residents will be able to screen for a genetic condition which causes high cholesterol levels at a subsidised rate as part of a nationwide programme launching on June 30. In a statement on June 19, the Ministry of Health (MOH) said that the new genetic testing programme for familial hypercholesterolaemia (FH) comes amid broader efforts to enhance preventive care in Singapore. The initiative aims to identify individuals with FH early and reduce the risk of premature heart disease with timely interventions. FH is a hereditary condition that impacts the body's ability to process cholesterol, affecting roughly 20,000 people in Singapore. People with the condition are up to 20 times more likely to experience heart attacks at a younger age compared with the general population. In a Facebook post on June 19, Health Minister Ong Ye Kung said that the Government is looking to expand preventive care based on genetic testing to more diseases beyond FH. 'It is part of our longer term effort to develop predictive preventive care under Healthier SG,' he said. As part of this effort, the ministry aims to open three genomic assessment centres (GACs) to ensure effective, efficient and sustainable delivery of genetic testing services within each healthcare cluster. Genetics testing for FH at these centres will be subsidised for eligible Singapore citizens and permanent residents (PRs). They can also tap on MediSave to offset the cost. Those referred to GACs will undergo: Pre-test genetic counselling to understand potential outcomes and benefits before consenting to the test Blood drawing and the genetic test Post-test genetic counselling, to understand the implications of the results The first GAC will be operated by SingHealth and located at the National Heart Centre. It will start accepting referrals from June 30. This centre will serve all Singapore residents until additional centres open. GACs operated by National Healthcare Group and National University Health System will subsequently open to cater to residents' needs. Immediate family members of those found with the condition are at risk and encouraged to undergo genetic testing, MOH said. Known as cascade screening, this process enables early detection of FH within families. It also allows for more timely intervention and treatment, such as advising them to adopt healthier lifestyles or starting on cholesterol-lowering therapies. Under the programme, Singapore citizens and PRs with abnormally high cholesterol levels may be referred by their doctors for genetic testing. Eligible Singaporeans and PRs can receive subsidies of up to 70 per cent for the costs, which include the genetic tests, pre-test and post-test counselling, and phlebotomy services. Seniors from the Pioneer Generation and Merdeka Generation are also eligible for additional subsidies. After subsidies, referred patients can expect to pay between US$117 (US$91.06) and US$575. Those eligible for cascade screening can expect to pay between US$53 and US$253 after subsidies. The MediSave500 and MediSave700 scheme can be used to further offset the cost of the genetic test after subsidies. Patients who are 60 years old and above may also use Flexi-MediSave to further defray out-of-pocket costs. Under a moratorium on genetic testing and insurance introduced by MOH and the Life Insurance Association Singapore (LIA) in 2021, life insurers here are banned from using predictive genetic test results in assessing the outcome of insurance applications, unless certain criteria are satisfied. Insurers are also not allowed to use genetic test results from biomedical research or direct-to-consumer genetic test results. MOH said it has worked with the LIA to amend the moratorium to disallow life insurers in Singapore to use the results of all genetic tests conducted under the national FH genetic testing programme. They may, however, continue to request for individuals to disclose existing diagnosed conditions and family history. The amended moratorium will take effect from June 30. - The Straits Times/ANN
Malay Mail
15-06-2025
- Malay Mail
Singapore's latest Covid-19 surge shows signs of slowing, says health minister as cases and hospitalisations fall
SINGAPORE, June 15 — Singapore's recent Covid-19 wave is on the decline, with the number of weekly infections dropping to about 15,300, down from a peak of 26,400 in late April, said Health Minister Ong Ye Kung. Describing the latest figures as 'encouraging', Ong noted in a Facebook post yesterday that the number of hospitalisations has also eased, falling to around 118 cases daily. At the height of the wave, hospitals were handling approximately 174 Covid-19 patients a day. 'The good news is that ICU (intensive care unit) cases remained consistently low throughout this wave, staying at just about two to three cases daily,' he said. 'This shows how our healthcare system has built up stronger resilience in managing Covid-19.' The minister also highlighted a drop in wastewater surveillance readings — a tool the authorities use to detect disease trends early. The falling levels add to evidence that the current wave is tapering off. However, Ong cautioned against complacency, noting that like seasonal influenza, future Covid-19 waves could still put significant pressure on healthcare resources. 'We will keep monitoring the situation closely, particularly the emergence of new variants, and update the public accordingly,' he said, stressing the importance of continued vigilance and preparedness for future pandemics.
Malaysian Reserve
11-06-2025
- Malaysian Reserve
MGI Tech Partners with Asia Pathogen Genomics Initiative to Advance Pathogen Genomics for Public Health in Asia
SINGAPORE, June 11, 2025 /PRNewswire/ — MGI Tech Co., Ltd. ('MGI'), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative ('Asia PGI'), part of the Duke-NUS Centre for Outbreak Preparedness (COP), have recently announced collaboration aimed at enhancing pathogen genomics sequencing efforts across Asia. This collaboration underscores a shared commitment to supporting public health initiatives through advanced life science technology. As part of this collaboration, MGI and Asia PGI will jointly democratize the pathogen genomics sequencing technology in Singapore and across Asia. The collaborative efforts will include hosting webinars to provide practical knowledge in pathogen genomics sequencing and delivering hands-on technical training to institutions and laboratories aimed at improving capacity development in pathogen detection. In addition, MGI also announced the launch of the MGI APAC Pandemic Preparedness Program (PPP) to strengthen the capabilities of genomics institutions and laboratories in pathogen surveillance. In collaboration with Asia PGI, the PPP aims to broaden the scope of pathogen surveillance solutions available to partner countries. The program offers a differentiated and sustainable alternative, focusing on application-centric and workflow-driven solutions. For example, it supports the development of equitable, effective, relevant, and validated workflow solutions to address acute infectious diseases. 'At the Duke-NUS Centre for Outbreak Preparedness, we believe that equitable access to pathogen genomic sequencing is fundamental to strengthening health security across South and Southeast Asia,' said Paul Pronyk, Director of COP. 'By collaborating with industry partners such as MGI, we are committed to ensuring that all communities in our region benefit from the latest advances in pathogen genomics – enabling early detection, informed response and ultimately, a healthier future for all.' 'We are proud to partner with Asia PGI to accelerate the application of cutting-edge sequencing technology in pathogen genomics,' said Roy Tan, General Manager of MGI Asia Pacific. 'Pathogen control is a pressing challenge for many countries in Asia. This partnership aims to improve the accessibility of pathogen genomics, empowering researchers and public health professionals in their fight against infectious diseases.' In response to the growing demand for rapid and precise detection of infectious diseases, MGI has developed a diverse array of comprehensive products for various applications, including metagenomic sequencing, targeted sequencing, and whole genome sequencing of pathogenic microorganisms. Looking ahead, MGI is committed to continuing its innovation, providing automated, convenient, and efficient core tools for pathogen identification, drug resistance analysis, and traceability. For more information of PPP, please visit: About the Duke-NUS Centre for Outbreak Preparedness (COP) and its Asia Pathogen Genomic Initiative (Asia PGI) The Duke-NUS Centre for Outbreak Preparedness (COP) was established in 2022 to address the growing need for enhanced preparedness and response to infectious disease outbreaks in the Asian region. With a mission to bridge the gap between research, training, policy and practice, COP aims to enhance regional health security across South and Southeast Asia. The Asia Pathogen Genomic Initiative (Asia PGI) is a flagship initiative of COP, aiming to harness scientific and technical partnerships across Singapore and Asia to advance genomic sequencing for infectious disease elimination. For more information, please visit About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.
